N2-[(苄氧基)羰基]-L-赖氨酰胺盐酸盐(1:1) | 112785-42-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N2-[(苄氧基)羰基]-L-赖氨酰胺盐酸盐(1:1)
• 英文名称: Z-Lys-NH2 hcl
• 英文别名: benzyl N-[(2S)-1,6-diamino-1-oxohexan-2-yl]carbamate;hydrochloride
• CAS: 112785-42-9
• 化学式: C₁₄H₂₁N₃O₃*ClH
• 分子量: 315.8
• InChiKey: MDEZKXTTYPBMFC-YDALLXLXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.32
• 重原子数：
  21
• 可旋转键数：
  9
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  107
• 氢给体数：
  4
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N2-[(苄氧基)羰基]-L-赖氨酰胺盐酸盐(1:1) 在 4-二甲氨基吡啶 、 sodium tetrahydroborate 、 magnesium sulfate 、 三乙胺 、 N,N-二异丙基乙胺 、 三氟乙酸酐 、 肼 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 5.17h， 生成 tert-butyl 2-[[2-(2-methoxyethoxymethoxy)phenyl]methyl-[(2S)-2-[[2-(2-methoxyethoxymethoxy)phenyl]methyl-[2-[(2-methylpropan-2-yl)oxy]-2-oxoethyl]amino]-6-(2-trimethylsilylethoxycarbonylamino)hexyl]amino]acetate
  参考文献：
  名称：

  Contrast enhancement agents and method of use thereof

  摘要：

  提供了一种对比剂组合物和一种诊断成像方法。该组合物包括一种药用载体和一种金属配合物，其包括具有结构（XXX）的配体：其中R1、R2、R3、R7、R8、R′1、R′2、R′3、R7′和R8′从氢、受保护的C1-C3羟基烷基或C1-C3烷基中选择；R4、R′4从氢、羟基、受保护的羟基基团、受保护的C1-C3羟基烷基或C1-C3烷基中选择；n是0到4之间的整数；R5、R′5从氢、包含C1-C30脂肪基、C3-C30环脂基、C2-C30芳香基的保护基中选择；m是1到10之间的整数；R7和R′7中的至少一个是酸性基团或受保护的酸性基团；Y包括蛋白质或肽基团、粒子、胶束、脂质体、有机分子、寡聚体、聚合物或亲水基团。

  公开号：

  US09155804B2

文献信息

• BIFUNCTIONAL CHELATING AGENTS
  申请人：GENERAL ELECTRIC COMPANY

  公开号：US20140088314A1

  公开（公告）日：2014-03-27

  A chelating agent, a metal-chelate, and a contrast agent are provided, wherein the chelating agent comprises a compound of structure (I) wherein R 1 , R 2 , R 3 , R 8 , R 7 , R′ 7 R′ 1 , R′ 2 , R′ 3 and R 8 ′ are selected from a hydrogen, a protected C 1 -C 3 hydroxyalkyl group, a C 1 -C 3 alkyl group; R 4 and R′ 4 are selected from a hydrogen, a hydroxyl group, a protected hydroxy group, a protected C 1 -C 3 hydroxyalkyl group, a C 1 -C 3 alkyl group; n is an integer between 0 and 4; R 5 and R′ 5 are selected from a hydrogen, a protecting group selected from the group consisting of C 1 -C 30 aliphatic radicals, C 3 -C 30 cycloaliphatic radicals, C 2 -C 30 aromatic radicals; R 9 and R′ 9 are selected form a hydrogen or a protecting group selected from the group consisting of C 1 -C 30 aliphatic radicals, C 3 -C 30 cycloaliphatic radicals, C 2 -C 30 aromatic radicals, m is an integer between 0 and 10; and at least one of R 7 and R′ 7 is acidic group or a protected acidic group.

  提供了一种螯合剂、金属螯合物和对比剂，其中螯合剂包括结构（I）的化合物，其中R1、R2、R3、R8、R7、R′7、R′1、R′2、R′3和R8′从氢、受保护的C1-C3羟基烷基基团、C1-C3烷基基团中选择；R4和R′4从氢、羟基、受保护的羟基、受保护的C1-C3羟基烷基基团、C1-C3烷基基团中选择；n是0到4之间的整数；R5和R′5从氢、选自C1-C30脂肪基、C3-C30环脂肪基、C2-C30芳香基的保护基中选择；R9和R′9从氢或选自C1-C30脂肪基、C3-C30环脂肪基、C2-C30芳香基的保护基中选择；m是0到10之间的整数；并且R7和R′7中的至少一个是酸性基团或受保护的酸性基团。
• Pyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof
  申请人：Teranishi Hirotaka

  公开号：US20060166899A1

  公开（公告）日：2006-07-27

  The present invention provides pyrazole derivatives represented by the general formula: wherein R 1 represents H, an optionally substituted C 1-6 alkyl group etc.; one of Q and T represents a group represented by the general formula: or a group represented by the general formula: while the other represents an optionally substituted C 1-6 alkyl group etc.; R 2 represents H, a halogen atom, OH, an optionally substituted C 1-6 alkyl group etc.; X represents a single bond, O or S; Y represents a single bond, a C 1-6 alkylene group etc.; Z represents CO or SO 2 ; R 4 and R 5 represent H, an optionally substituted C 1-6 alkyl group etc.; and R 3 , R 6 and R 7 represent H, a halogen atom etc., pharmaceutically acceptable salts thereof or prodrugs thereof, which exhibit an excellent inhibitory activity in human SGLT1 and are useful as agents for the prevention or treatment of a disease associated with hyperglycemia such as diabetes, diabetic complications or obesity, and pharmaceutical compositions comprising the same, pharmaceutical uses thereof, and intermediates for production thereof.

  本发明提供了由下式表示的吡唑衍生物： 其中，R1代表H、可选取代的C1-6烷基等；Q和T中的一个代表由下式表示的基团： 另一个代表可选取代的C1-6烷基等；R2代表H、卤素原子、OH、可选取代的C1-6烷基等；X代表单键、O或S；Y代表单键、C1-6烷基亚基等；Z代表CO或SO2；R4和R5代表H、可选取代的C1-6烷基等；R3、R6和R7代表H、卤素原子等，其药学上可接受的盐或前药，具有在人类SGLT1中出色的抑制活性，并且作为预防或治疗与高血糖相关的疾病，如糖尿病、糖尿病并发症或肥胖症的药物，以及包含它们的制药组合物、制药用途和制备它们的中间体。
• Higher order iminodiacetic acid libraries for probing protein–protein interactions
  作者：Dale L. Boger、Joel Goldberg、Weiqin Jiang、Wenying Chai、Pierre Ducray、Jae Kyoo Lee、Rachel S. Ozer、Carl-Magnus Andersson

  DOI：10.1016/s0968-0896(98)00128-x

  日期：1998.8

  Full details of the preparation of iminodiacetic acid diamide dimer (2040 compounds), trimer (560 compounds), and tetramer (1596 compounds) libraries by multistep convergent solution-phase synthesis for studying protein-protein interactions are provided. The libraries were assembled in a format providing small 8-10 compound mixtures and the deconvolution of many of the small mixtures to identify screening leads by resynthesis of the individual components have been conducted for 320 of the individual compounds to date. A representative example of the subsequent exploration of the structure-activity relationships for an identified receptor binding antagonist (200 additional individual compounds) and steps taken for potential elaboration to a receptor dimerization agonist are defined with preparation of representative linked dimers (70 compounds). (C) 1998 Elsevier Science Ltd. All rights reserved.
• PYRAZOLE DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, MEDICINAL USE THEREOF, AND INTERMEDIATE FOR PRODUCTION THEREOF
  申请人：Kissei Pharmaceutical Co., Ltd.

  公开号：EP1544208B1

  公开（公告）日：2010-05-26
• US5942493A
  申请人：——

  公开号：US5942493A

  公开（公告）日：1999-08-24